Novartis: Myelodysplastic Syndromes trials

The registry lists 37 Myelodysplastic Syndromes studies with Novartis as lead sponsor. 0 are open to participants now and 21 have results posted.

Phase 1 11Phase 2 19Phase 3 4Phase 4 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDSTerminatedNCT04878432Phase 2Results posted
• A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS ParticipantsTerminatedNCT04812548Phase 2Results posted
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)TerminatedNCT04266301Phase 3Results posted
• A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).TerminatedNCT03946670Phase 2Results posted
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) FormulationCompletedNCT02720536Phase 3Results posted
• A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.TerminatedNCT02663752Phase 2Results posted
• A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)TerminatedNCT02158936Phase 3Results posted
• Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)CompletedNCT02125877Phase 2Results posted
• A Rollover Study to Provide Continued Treatment With EltrombopagCompletedNCT01957176Phase 4Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood TransplantCompletedNCT01930162Phase 2Results posted
• Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.CompletedNCT01868477Phase 2Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
• A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT01440374Phase 2Results posted
• Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability StudyTerminatedNCT01326845Phase 4Results posted
• LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)TerminatedNCT01034657Phase 2Results posted
• A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).CompletedNCT00946647Phase 1/2Results posted
• Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy StudyCompletedNCT00940602Phase 2Results posted
• Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron OverloadCompletedNCT00600938Phase 2Results posted
• Study for the Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00117507Phase 4Results posted
• Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00110266Phase 2Results posted
• PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)CompletedNCT00045942Phase 1/2Results posted
• Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesActive, not recruitingNCT05552469Phase 1
• A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsWithdrawnNCT05367401Phase 1/2
• Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active, not recruitingNCT05201066Phase 2
• Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSTerminatedNCT04810611Phase 1
• Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion DependenceActive, not recruitingNCT04797000Phase 2
• Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
• A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 MutationsActive, not recruitingNCT02381886Phase 1
• A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedNCT02078609Phase 1
• A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) PatientsCompletedNCT01613976Phase 1
• This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.CompletedNCT01250951Phase 4
• Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.TerminatedNCT01066468Phase 1
• Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadCompletedNCT00673608Phase 4
• Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron OverloadCompletedNCT00564941Phase 4
• Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron OverloadCompletedNCT00481143Phase 4
• A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron OverloadCompletedNCT00171821Phase 3
• Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic AnemiasCompletedNCT00061763Phase 2